scholarly journals 122: G-CSF and FLT3 Ligand Promote Recovery of Hematopoiesis after Total Body Irradiation (TBI) without Hematopoietic Stem Cell Support

2008 ◽  
Vol 14 (2) ◽  
pp. 47
Author(s):  
G.E. Georges ◽  
J.N. Pillai ◽  
V. Lesnikov ◽  
M. Lesnikova ◽  
Y.-J. Yang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Total Body Irradiation ◽  
Flt3 Ligand ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Total Body ◽  
Cell Support

scholarly journals Mesenchymal Stromal Cell-Derived Extracellular Vesicles Provide Long-Term Survival After Total Body Irradiation Without Additional Hematopoietic Stem Cell Support

Stem Cells ◽  
2017 ◽  
Vol 35 (12) ◽  
pp. 2379-2389 ◽  
Author(s):  
Jill-Sandra Schoefinius ◽  
Bärbel Brunswig-Spickenheier ◽  
Thomas Speiseder ◽  
Sabrina Krebs ◽  
Ursula Just ◽  
...  
Keyword(s):  
Stem Cell ◽  
Total Body Irradiation ◽  
Mesenchymal Stromal Cell ◽  
Stromal Cell ◽  
Term Survival ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Total Body ◽  
Cell Support

scholarly journals High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

2006 ◽  
Vol 17 (10) ◽  
pp. 1479-1488 ◽  
Author(s):  
P. Pedrazzoli ◽  
J.A. Ledermann ◽  
J.-P. Lotz ◽  
S. Leyvraz ◽  
M. Aglietta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Solid Tumors ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

scholarly journals Total body irradiation in a case of thalassemia major with source to axis distance based planning: A case report

2020 ◽  
pp. 25-28
Author(s):  
Mayuresh D. Virkar ◽  
Rajkumar Chauhan ◽  
Pranav Chadha ◽  
Kaustav Talapatra ◽  
Reuben Jake Rodrigues ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Total Body Irradiation ◽  
Conditioning Regimen ◽  
Thalassemia Major ◽  
Entire Body ◽  
Hematopoietic Stem ◽  
Total Body

Background: The use of total body radiation (TBI) before hematopoietic stem cell transplantation (HSCT) would increase the engraftment without transplant-related morbidity or mortality among Thalassemia major (TM) cases. Case presentation: A 2-year-old female child, diagnosed with TM was scheduled for haploidentical allogenic transplant-based protocol, and after that, based on protocol she was scheduled to undergo a single session of TBI as a conditioning regimen before haploidentical allogenic hematopoietic stem cell tranplant. A total dose of 4 Gy was administered.. The incidence of graft failure was reduced as TBI was used before allogeneic stem cell transplantation. TBI provided a uniform dose of radiation to the entire body, penetrating areas such as the central nervous system (CNS) and testes. Conclusion: Total Body Irradiation with the SAD technique is the most effective way of treatment. As it is comfortable for the patient to undergo, easily reproducible, and it helps to achieve a uniform dose distribution.

Radiation-induced kidney injury

2019 ◽  
Vol 3 (3) ◽  
pp. 160-167 ◽  
Author(s):  
Jaya Kala
Keyword(s):  
Experimental Data ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Radiation Exposure ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Total Body Irradiation ◽  
Hematopoietic Stem ◽  
Total Body

Renal dysfunction because of radiation exposure was recognized decades ago. The incidence declined when more effective chemotherapeutic agents became available. However, there appears to be a resurgence with the advent of total body irradiation used prior to hematopoietic stem cell transplantation. Several chemotherapeutic drugs used prior to total body irradiation have some ionizing radiation potentiating effects. Chronic kidney disease that occurs after hematopoietic stem cell transplantation is known to occur due to nephrotoxicity from medications, graft-versus-host disease, and the currently under-recognized radiation exposure. The clinical features vary depending on the dose of radiation and the volume of single or bilateral kidneys exposed. The usual symptoms of fatigue, edema, anemia, malignant hypertension, azotemia, and shortness of breath appear in 6–12 months of exposure. Since this is an under-recognized entity, there are no large controlled trials to guide therapy. This review highlights some of the experimental data that have shown some promising results for treatment. There is need for further studies on the current incidence and prevalence and clinical trials to guide treatment, based on the experimental data available.

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

1997 ◽  
Vol 15 (5) ◽  
pp. 1870-1879 ◽  
Author(s):  
K H Antman ◽  
P A Rowlings ◽  
W P Vaughan ◽  
C J Pelz ◽  
J W Fay ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Autologous Blood ◽  
Locally Advanced ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
National Cooperative ◽  
Cell Support

PURPOSE To identify trends in high-dose therapy with autologous hematopoietic stem-cell support (autotransplants) for breast cancer (1989 to 1995). PATIENTS AND METHODS Analysis of patients who received autotransplants and were reported to the Autologous Blood and Marrow Transplant Registry. Between January 1, 1989 and June 30, 1995, 19,291 autotransplants were reviewed; 5,886 were for breast cancer. Main outcomes were progression-free survival (PFS) and survival. RESULTS Between 1989 and 1995, autotransplants for breast cancer increased sixfold. After 1992, breast cancer was the most common indication for autotransplant. Significant trends included increasing use for locally advanced rather than metastatic disease (P < .00001) and use of blood-derived rather than marrow-derived stem cells (P < .00001). One-hundred-day mortality decreased from 22% to 5% (P < .0001). Three-year PFS probabilities were 65% (95% confidence intervals [Cls], 59 to 71) for stage 2 disease, and 60% (95% Cl, 53 to 67) for stage 3 disease. In metastatic breast cancer, 3-year probabilities of PFS were 7% (95% Cl, 4 to 10) for women with no response to conventional dose chemotherapy; 13% (95% Cl, 9 to 17) for those with partial response; and 32% (95% Cl, 27 to 37) for those with complete response. Eleven percent of women with stage 2/3 disease and less than 1% of those with stage 4 disease participated in national cooperative group randomized trials. CONCLUSION Autotransplants increasingly are used to treat breast cancer. One-hundred-day mortality has decreased substantially. Three-year survival is better in women with earlier stage disease and in those who respond to pretransplant chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document